EA201270818A1 - 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ - Google Patents
6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТInfo
- Publication number
- EA201270818A1 EA201270818A1 EA201270818A EA201270818A EA201270818A1 EA 201270818 A1 EA201270818 A1 EA 201270818A1 EA 201270818 A EA201270818 A EA 201270818A EA 201270818 A EA201270818 A EA 201270818A EA 201270818 A1 EA201270818 A1 EA 201270818A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methyl
- met
- inhibitor
- iltio
- indazol
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36933510P | 2010-07-30 | 2010-07-30 | |
| PCT/US2011/044926 WO2012015677A1 (en) | 2010-07-30 | 2011-07-22 | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201270818A1 true EA201270818A1 (ru) | 2013-05-30 |
Family
ID=44513148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270818A EA201270818A1 (ru) | 2010-07-30 | 2011-07-22 | 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8268836B2 (enExample) |
| EP (1) | EP2598144B1 (enExample) |
| JP (1) | JP5738412B2 (enExample) |
| KR (1) | KR20130052740A (enExample) |
| CN (1) | CN103002898A (enExample) |
| AR (1) | AR085183A1 (enExample) |
| AU (1) | AU2011282973B2 (enExample) |
| BR (1) | BR112013002211A2 (enExample) |
| CA (1) | CA2805494A1 (enExample) |
| EA (1) | EA201270818A1 (enExample) |
| ES (1) | ES2516940T3 (enExample) |
| IN (1) | IN2012MN02924A (enExample) |
| MX (1) | MX2013001247A (enExample) |
| TW (1) | TWI431008B (enExample) |
| WO (1) | WO2012015677A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2869316C (en) * | 2012-05-09 | 2016-12-20 | Eli Lilly And Company | Anti-c-met antibodies |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US10386376B2 (en) | 2015-11-09 | 2019-08-20 | Jeimei, Llc | Sample container with integrated test strip |
| CN108853108A (zh) * | 2015-12-31 | 2018-11-23 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728017B2 (en) * | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| CN101553490A (zh) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | 用作蛋白激酶调节剂的二环三唑类化合物 |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| EA016527B1 (ru) | 2006-10-23 | 2012-05-30 | ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. | Триазолопиридазиновые модуляторы протеинкиназ |
| PA8792501A1 (es) * | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
-
2011
- 2011-07-20 AR ARP110102632A patent/AR085183A1/es unknown
- 2011-07-22 CN CN2011800371928A patent/CN103002898A/zh active Pending
- 2011-07-22 EP EP11741372.4A patent/EP2598144B1/en not_active Not-in-force
- 2011-07-22 ES ES11741372.4T patent/ES2516940T3/es active Active
- 2011-07-22 AU AU2011282973A patent/AU2011282973B2/en not_active Expired - Fee Related
- 2011-07-22 JP JP2013521838A patent/JP5738412B2/ja not_active Expired - Fee Related
- 2011-07-22 KR KR1020137002382A patent/KR20130052740A/ko not_active Ceased
- 2011-07-22 CA CA2805494A patent/CA2805494A1/en not_active Abandoned
- 2011-07-22 US US13/188,496 patent/US8268836B2/en not_active Expired - Fee Related
- 2011-07-22 TW TW100126076A patent/TWI431008B/zh not_active IP Right Cessation
- 2011-07-22 MX MX2013001247A patent/MX2013001247A/es not_active Application Discontinuation
- 2011-07-22 WO PCT/US2011/044926 patent/WO2012015677A1/en not_active Ceased
- 2011-07-22 BR BR112013002211A patent/BR112013002211A2/pt not_active IP Right Cessation
- 2011-07-22 EA EA201270818A patent/EA201270818A1/ru unknown
-
2012
- 2012-12-31 IN IN2924MUN2012 patent/IN2012MN02924A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2516940T3 (es) | 2014-10-31 |
| TWI431008B (zh) | 2014-03-21 |
| US8268836B2 (en) | 2012-09-18 |
| JP2013532687A (ja) | 2013-08-19 |
| BR112013002211A2 (pt) | 2016-05-24 |
| AR085183A1 (es) | 2013-09-18 |
| WO2012015677A9 (en) | 2012-12-13 |
| EP2598144A1 (en) | 2013-06-05 |
| MX2013001247A (es) | 2013-03-18 |
| WO2012015677A1 (en) | 2012-02-02 |
| IN2012MN02924A (enExample) | 2015-06-12 |
| KR20130052740A (ko) | 2013-05-23 |
| AU2011282973B2 (en) | 2014-03-20 |
| AU2011282973A1 (en) | 2013-01-10 |
| CN103002898A (zh) | 2013-03-27 |
| EP2598144B1 (en) | 2014-08-13 |
| JP5738412B2 (ja) | 2015-06-24 |
| US20120028984A1 (en) | 2012-02-02 |
| CA2805494A1 (en) | 2012-02-02 |
| TW201219393A (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| BR112013002211A2 (pt) | 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-met | |
| EA201491456A1 (ru) | Соединения-ингибиторы raf | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| MX349950B (es) | Profarmacos de treprostinil enlazados a un portador. | |
| MX2019010446A (es) | Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| CR20140229A (es) | Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona | |
| BR112017019286A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável deste | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| EA200970402A1 (ru) | Триазолопиридазиновые модуляторы протеинкиназ | |
| EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| CR20130023A (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
| EA201491391A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA028821B9 (ru) | Соединения и способы для модуляции киназ, а также показания к их применению | |
| MX372740B (es) | Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak. | |
| BR112016029825A2 (pt) | composto | |
| MX2016007128A (es) | Compuestos del receptor 6 de quimiocina (ccr6). | |
| CL2011001947A1 (es) | Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular. | |
| EA201591024A1 (ru) | Димерные соединения |